NICE has recommended vutrisiran for routine NHS use in adults with transthyretin amyloidosis with cardiomyopathy, offering a new disease-modifying option alongside tafamidis.
Medscape News UK
Source link : https://www.medscape.com/viewarticle/nice-endorses-vutrisiran-attr-cm-treatment-2025a1000wi7?src=rss
Author :
Publish date : 2025-11-21 13:49:00
Copyright for syndicated content belongs to the linked Source.
